Commercial Biobank Licensing Law In Russia.
1. Introduction
Commercial Biobank Licensing Law in Russia concerns the legal regulation of private companies, biotechnology enterprises, medical institutions, pharmaceutical businesses and research organisations that collect, store, process, preserve and commercially use human biological materials and associated genetic information.
A commercial biobank is an organisation or facility that maintains biological specimens, such as:
Human blood, plasma and serum.
DNA, RNA and genetic samples.
Human tissues and cells.
Tumour and biopsy specimens.
Reproductive materials, including sperm and eggs.
Biological samples collected for pharmaceutical research and clinical trials.
Commercial biobanking raises important legal questions concerning licensing, patient consent, ownership of biological materials, genetic privacy, commercial research, cross-border transfers, intellectual property and liability.
An important distinction: Russia does not have one comprehensive statutory licence specifically called a commercial biobank licence. Instead, the applicable legal requirements depend on the activities performed by the organisation. Medical services, pharmaceutical activities, clinical research, genetic testing and work involving potentially hazardous biological agents may attract different regulatory requirements.
2. Main legal framework governing commercial biobanks
The principal legal instruments are the following.
| Legislation | Legal significance |
|---|---|
| Constitution of the Russian Federation, Articles 21, 23 and 24 | Human dignity, privacy and protection of personal information |
| Federal Law No. 323-FZ of 21 November 2011 | Healthcare, informed consent and medical confidentiality |
| Federal Law No. 152-FZ of 27 July 2006 | Personal-data protection |
| Federal Law No. 99-FZ of 4 May 2011 | Licensing of regulated activities |
| Federal Law No. 180-FZ of 23 June 2016 | Biomedical cellular products and biological-material donation |
| Federal Law No. 61-FZ of 12 April 2010 | Circulation and regulation of medicinal products |
| Government Resolution No. 852 of 1 June 2021 | Licensing of medical activities |
| Government Resolution No. 547 of 31 March 2022 | Licensing of pharmaceutical activities |
These laws must be applied according to the actual activities of the biobank rather than merely its commercial name.
A. Federal Law No. 323-FZ: Healthcare protection
This is one of the most important statutes for commercial biobanking.
Its provisions regulate relationships between patients, donors, medical organisations and other healthcare participants.
Three provisions are particularly relevant:
Article 13 – Medical confidentiality
Medical organisations must protect confidential information concerning patients, including information relating to medical examinations, diagnoses and treatment.
A commercial biobank receiving identifiable clinical specimens must establish appropriate confidentiality safeguards.
For example, a company storing cancer biopsy specimens cannot freely disclose patients' identities or medical histories to pharmaceutical companies simply because those companies pay for access to the samples.
Article 20 – Informed voluntary consent
Medical intervention generally requires informed voluntary consent, subject to statutory exceptions.
Where a biobank obtains biological material through a medical procedure, the applicable consent requirements must be satisfied.
Consent documentation should explain:
The nature of sample collection.
The purpose of storage.
The intended research activities.
Whether commercial research is contemplated.
Whether samples may be transferred to third parties.
The duration of storage.
Conditions for withdrawal or destruction, where legally applicable.
Article 22 – Information about health
Patients have rights concerning information about their health and medical documentation.
Consequently, commercial biobanks and associated medical organisations must consider how donors can access relevant information and how confidential medical records are protected.
B. Federal Law No. 152-FZ: Personal-data protection
This legislation is particularly important when a biobank stores genetic information alongside identifiable donor records.
A commercial biobank may process:
Names and identification details.
Medical histories.
Genetic test results.
Sample identification codes.
Clinical research records.
Information concerning inherited conditions.
The organisation must establish a lawful basis for processing, comply with applicable consent requirements, protect information against unauthorised access and respect statutory restrictions on disclosure.
Pseudonymisation does not necessarily make information anonymous. If the biobank can reconnect a sample code with an individual, the associated information may remain personal data.
Legal significance: A company cannot assume that purchasing or receiving a biological sample automatically gives it unrestricted rights over the donor's genetic information.
C. Federal Law No. 99-FZ: Licensing of certain activities
Federal Law No. 99-FZ provides the general framework for state licensing.
The crucial distinction is between:
Establishing and operating a facility that stores biological samples.
Performing medical procedures.
Conducting medical laboratory examinations.
Manufacturing regulated biomedical products.
Conducting regulated pharmaceutical activities.
A standalone facility performing only scientific storage does not automatically require a separate medical licence merely because it is called a biobank.
However, if the company performs activities falling within a licensed category, the corresponding licence must be obtained.
D. Federal Law No. 180-FZ: Biomedical cellular products
Federal Law No. 180-FZ regulates biomedical cellular products, including their development, clinical trials, production, quality control, registration, storage, transportation and distribution.
Article 1 defines the scope of the statute and expressly distinguishes certain activities outside its coverage, including the handling of human cells and tissues for scientific and educational purposes.
Article 2 defines biological material and biomedical cellular products.
This distinction is important because a commercial biobank storing tissue for academic research is not necessarily subject to the same licensing regime as a manufacturer producing a biomedical cellular product for therapeutic use.
A company moving from sample storage into cellular-product manufacturing must therefore reassess its regulatory obligations.
cis-legislation.com+3
3. Licensing requirements for commercial biobanks
Russia's regulatory approach requires an activity-based licensing assessment.
Activity-based licensing structure
Stage 1: Biological sample storage
Determine whether the organisation performs only scientific storage, preservation and inventory management.
Stage 2: Medical activities
If it collects samples through medical interventions, performs diagnostic procedures or provides other licensed medical services, assess medical licensing requirements.
Stage 3: Cellular-product manufacturing
If the organisation manufactures regulated biomedical cellular products, apply the special requirements of Federal Law No. 180-FZ.
Stage 4: Pharmaceutical activities
If it undertakes activities classified as pharmaceutical activities, determine the relevant licence and regulatory conditions.
A. Medical activity licensing
Government Resolution No. 852 of 1 June 2021 establishes the licensing framework for medical activities.
The licensing regime includes specified medical works and services.
A commercial biobank that independently conducts medical examinations, sample collection as a medical intervention or diagnostic testing must assess whether those activities fall within the licensed list.
The licence assessment concerns the actual work performed, the premises, equipment, personnel and applicable professional requirements.
The licensing rules under Resolution No. 852 are currently scheduled to remain in force until 1 September 2027.
Consultant Plus+1
B. Pharmaceutical activity licensing
Government Resolution No. 547 of 31 March 2022 establishes the licensing rules for pharmaceutical activities.
A commercial biobank does not automatically become a pharmaceutical organisation because it supplies biological specimens to pharmaceutical manufacturers.
However, where the company itself undertakes activities falling within the statutory definition of pharmaceutical activity, the relevant licensing obligations apply.
Roszdravnadzor is an important licensing and supervisory authority in this area.
ealegislation.com+1
C. Licensing for biomedical cellular-product manufacturing
Where biological materials are processed into regulated biomedical cellular products, Federal Law No. 180-FZ becomes particularly important.
The law distinguishes the producer of a biomedical cellular product from an ordinary biological-material storage facility.
A manufacturer must comply with the applicable licensing, quality, safety, clinical-trial and registration requirements.
A biobank cannot avoid these requirements simply by describing manufacturing as sample preservation.
4. Application procedure and institutional compliance
A commercial biobank planning to operate in Russia should undertake the following compliance steps.
Step 1: Establish the legal entity
The organisation must establish an appropriate legal structure and register its commercial activities.
Its constitutional documents and business arrangements should accurately describe its intended activities.
Step 2: Define the regulatory classification
The organisation should identify whether it will undertake:
Scientific sample storage.
Clinical sample collection.
Genetic testing.
Medical laboratory services.
Pharmaceutical research.
Biomedical cellular-product manufacturing.
Each activity should be assessed separately.
Step 3: Establish suitable premises
The facility should have appropriate infrastructure for its particular materials and activities.
This may include:
Controlled-temperature storage.
Cryogenic storage facilities.
Refrigeration and monitoring systems.
Backup power supplies.
Access-control systems.
Biological-waste management.
Emergency response procedures.
Step 4: Employ qualified personnel
Personnel conducting regulated medical, laboratory or manufacturing activities must satisfy the relevant qualification requirements.
Step 5: Establish consent and documentation procedures
The organisation should maintain donor consent documents, collection records, sample identifiers, storage records and transfer agreements.
Step 6: Obtain applicable licences
Applications must be submitted to the competent licensing authority for each regulated activity.
Step 7: Establish continuous compliance
The biobank should maintain procedures for inspections, internal audits, sample traceability, incident reporting and regulatory documentation.
5. Donor consent and commercial exploitation of biological materials
One of the most difficult legal questions is whether biological materials collected from a person can subsequently be used for commercial research.
The Russian legal framework does not establish a simple rule that a donor's consent to collection automatically authorises every future commercial use.
The legal relationship depends on the purpose of collection, the type of material, the contractual arrangements and applicable healthcare and data-protection legislation.
Important legal principles
1. Purpose limitation
A sample collected for diagnostic purposes should not automatically be treated as available for unrelated commercial research.
2. Informed consent
Donors should receive understandable information about the proposed collection, storage and research purposes.
3. Separate data protection
Consent to biological sample collection and consent to processing personal data should be legally distinguished.
4. Third-party access
Agreements with pharmaceutical companies and research institutions should specify permitted purposes, confidentiality obligations and restrictions on onward transfers.
5. Withdrawal and destruction
The consent and storage agreement should explain the conditions under which donors may withdraw permission and request destruction of stored materials, taking account of applicable legal exceptions and the consequences of research already performed.
Russian academic legal scholarship has specifically identified the need for clearer rules governing the legal personality of biobanks, the legal status of biological samples and separate consent for sample handling and personal-data processing.
Право. Журнал Высшей школы экономики+1
6. Important case laws and judicial decisions
There is an important limitation in Russian biobank jurisprudence: there is no clearly established body of reported Russian Supreme Court decisions creating a comprehensive licensing doctrine specifically for commercial biobanks. Nevertheless, decisions concerning cryopreserved biological materials, privacy, medical consent and genetic samples provide important legal guidance.
Case 1. Third Cassation Court of General Jurisdiction, 29 April 2026, Case No. 8G-4098/2026 [88-6166/2026]
Russian judicial decision
Subject: Ownership, inheritance and control of cryopreserved biological material.
The dispute concerned parents seeking legal recognition of their rights to use cryopreserved biological material belonging to their deceased child.
The courts considered Federal Law No. 323-FZ, the legislation on transplantation of human organs and tissues, and Ministry of Health Order No. 803n concerning assisted reproductive technologies.
The courts rejected the claim, reasoning that the biological material did not form part of the deceased child's inheritable estate and that the parents could not obtain rights to use it through inheritance.
Legal principles:
Biological material does not necessarily constitute ordinary inheritable property.
Family relationships do not automatically confer authority to dispose of another person's stored biological material.
Cryopreservation agreements and statutory restrictions must be considered.
Contractual and statutory rights concerning biological material must be distinguished from ordinary ownership rights.
Relevance to commercial biobanks:
A commercial biobank should not assume that stored specimens can automatically be transferred to a donor's heirs following the donor's death.
Its agreements should expressly address death, continued storage, authorised use, destruction and disputes concerning access.
ГАРАНТ
Case 2. S. and Marper v. United Kingdom (2008), European Court of Human Rights, Applications Nos. 30562/04 and 30566/04
Comparative human-rights authority
Subject: Retention of biological samples and DNA profiles.
The applicants challenged the retention of their fingerprints, cellular samples and DNA profiles after criminal proceedings against them had ended.
The European Court of Human Rights held that retaining cellular samples and DNA profiles interfered with the applicants' right to respect for private life under Article 8 of the European Convention on Human Rights.
The Court emphasised that cellular samples contain highly sensitive genetic and health information.
It found that the blanket and indefinite retention of the applicants' information was disproportionate.
Legal principles:
Biological samples contain sensitive personal information.
Retention itself can interfere with privacy.
Storage must have a legitimate and sufficiently defined purpose.
Retention periods and access must be appropriately controlled.
Data protection safeguards are essential.
Relevance to Russia:
This is a comparative human-rights authority, not a Russian commercial-biobank licensing judgment. Its reasoning is useful when analysing privacy safeguards for genetic and biological repositories.
Russia ceased to be a party to the European Convention on Human Rights on 16 September 2022. The judgment should therefore not be presented as automatically creating current Convention obligations for post-withdrawal Russian conduct.
bailii.org+1
Case 3. Evans v. United Kingdom (2007), European Court of Human Rights, Application No. 6339/05
Subject: Consent, reproductive biological material and control over stored embryos.
The case concerned a dispute over the continued use of embryos created through IVF after one genetic contributor withdrew consent.
The European Court considered reproductive autonomy, consent and the competing rights of the individuals involved.
The Court upheld the relevant domestic legal framework, which required continuing consent from both genetic contributors.
Legal principles:
Consent to the creation of biological material does not necessarily mean permanent consent to every subsequent use.
Reproductive materials require particularly careful legal treatment.
The interests of different contributors may conflict.
Storage and use agreements must be sufficiently clear.
Relevance to commercial biobanks:
This judgment is particularly useful for businesses storing reproductive tissues, embryos, gametes and other materials whose use depends on continuing consent.
It is comparative jurisprudence rather than binding Russian commercial-biobank precedent.
Case 4. Russian biobank legal-status scholarship – Maleina (2020)
Reference: Marina N. Maleina, Legal Status of the Biobank (Bank of Biological Materials of Human Origin), Higher School of Economics Law Journal, 2020, pages 98–117.
This is an academic legal analysis, not a judicial decision.
The research examines the legal status of commercial and non-commercial biobanks, contractual arrangements for storing biological materials, donor confidentiality and the rights of organisations receiving samples.
It identifies two distinct categories of biobank property:
Property used to operate the facility.
Biological materials maintained by the facility.
The article also discusses commercial interests, research access and the special legal status of human biological materials.
Legal significance: It provides a useful foundation for understanding why ordinary commercial property principles cannot be applied mechanically to human biological samples.
Право. Журнал Высшей школы экономики
7. Ownership and intellectual-property rights in biological materials
Commercial biobanking creates complex ownership questions.
For example, a biotechnology company may receive a blood sample from a donor, extract DNA, develop a genetic database and use the resulting information in pharmaceutical research.
Four separate legal interests may arise.
| Legal interest | Main legal issue |
|---|---|
| Biological specimen | Lawful collection, possession, storage and permitted use |
| Genetic information | Privacy and personal-data protection |
| Research results | Intellectual-property and contractual rights |
| Biobank database | Database protection, confidentiality and data governance |
A. Ownership of biological samples
Russian law does not provide a complete, unified statutory ownership regime for every category of human biological material.
Consequently, the legal position should be determined by considering the relevant statutory rules, the purpose of collection and the agreements between donors and biobanks.
A donor's consent to storage should not automatically be interpreted as an unrestricted transfer of all personal rights concerning the material.
B. Intellectual property
Commercial biobanks may generate valuable scientific assets through:
DNA sequencing.
Genetic databases.
Biomarker discovery.
Disease-risk research.
Pharmaceutical screening.
Cellular research.
Computational analysis.
However, the commercial value of research results does not automatically eliminate the donor's privacy and consent rights.
The company must separately consider patentability, copyright, database rights, trade secrets and contractual restrictions.
C. Commercialisation agreements
Contracts between biobanks and pharmaceutical companies should identify:
Which specimens may be supplied.
Permitted research purposes.
Whether genetic testing is authorised.
Whether commercial product development is contemplated.
Who controls research results.
Whether onward transfers are permitted.
What happens to unused specimens.
What happens if the biobank closes.
8. Cross-border transfer of biological samples and genetic information
International commercial biobanking creates additional regulatory difficulties.
For example, a Russian biobank might supply tumour samples to a foreign pharmaceutical company for cancer-drug development.
The parties must distinguish between physical biological samples and associated electronic personal data.
Relevant issues include:
Lawful export of the biological material.
Customs and applicable sanitary requirements.
Donor consent for international research.
Personal-data transfer restrictions.
Confidentiality and security.
Contractual allocation of liability.
Restrictions applicable to particular biological materials or research programmes.
Under Federal Law No. 152-FZ, cross-border personal-data transfers are subject to statutory requirements, including the applicable rules under Article 12.
The fact that a foreign organisation receives only coded samples does not necessarily remove data-protection obligations if re-identification remains possible.
A Russian commercial biobank should therefore conduct a separate legal assessment before providing samples or associated genetic information to overseas research partners.
9. Regulatory authorities and enforcement
Several Russian authorities may become relevant depending on the activities of the commercial biobank.
| Authority | Regulatory responsibility |
|---|---|
| Ministry of Health | Healthcare policy and medical regulation |
| Roszdravnadzor | Medical and pharmaceutical licensing and supervision |
| Rospotrebnadzor | Sanitary and epidemiological supervision and relevant personal-data functions |
| Roskomnadzor | Personal-data protection supervision |
| Federal Antimonopoly Service | Competition-related issues |
| Federal Tax Service | Business registration and taxation |
A. Administrative liability
Under the Code of Administrative Offences of the Russian Federation:
Article 14.1: Relevant violations involving entrepreneurial activities without a required licence.
Article 19.20: Relevant violations involving activities without a licence where the activity is not connected with profit-making.
Article 13.11: Violations of personal-data legislation.
The precise liability depends on the nature of the violation, the organisation's legal status and the applicable statutory provisions.
B. Civil liability
A commercial biobank may face civil claims arising from:
Negligent sample preservation.
Unauthorised disclosure of genetic information.
Breach of storage contracts.
Incorrect sample identification.
Unauthorised commercial use.
Failure to comply with agreed destruction requirements.
C. Criminal liability
Depending on the circumstances, serious misconduct may also engage criminal legislation, including provisions concerning violations of privacy, unlawful disclosure of protected information and other offences.
10. Major legal challenges in commercial biobank licensing
1. Absence of a unified licensing category
Russia does not have one comprehensive licensing statute covering every type of commercial human biobank.
2. Uncertain ownership rights
The legal status of stored biological material is more complicated than ordinary commercial property.
3. Inadequate consent arrangements
Broad or poorly drafted consent forms can create disputes about future research and commercialisation.
4. Genetic-data confidentiality
Genetic information may reveal sensitive information about donors and their relatives.
5. Commercial exploitation
The interests of donors, biotechnology businesses, pharmaceutical companies and research institutions may conflict.
6. Long-term preservation
Biobanks must address equipment failures, contamination, sample deterioration, insolvency and organisational closure.
7. International research cooperation
Cross-border sample transfers and genetic-data processing require additional legal scrutiny.
11. Recommendations for strengthening Russian commercial biobank regulation
Several legislative and institutional reforms could improve legal certainty.
Introduce a specific statutory definition of a commercial human biobank.
Establish a dedicated licensing or registration framework for professional human biological-material repositories.
Introduce minimum standards for cryogenic storage and biological sample preservation.
Establish standardised donor-consent documentation.
Clarify the legal status of biological materials after a donor's death.
Establish rules for commercial access to biological specimens.
Strengthen genetic-data security and confidentiality requirements.
Introduce mandatory contingency arrangements for biobank insolvency or closure.
Clarify the rights and obligations of pharmaceutical research partners.
Develop specific procedures for international biological-material transfers.
12. Conclusion
Commercial Biobank Licensing Law in Russia is an emerging and specialised area of biotechnology and healthcare regulation.
The Russian legal framework combines medical licensing, pharmaceutical regulation, personal-data protection, biological-material donation rules and civil-law contractual principles.
Federal Laws No. 323-FZ, 152-FZ, 99-FZ and 180-FZ are particularly important, while Government Resolutions No. 852 and 547 provide important licensing requirements for medical and pharmaceutical activities.
The central legal issue is that operating a commercial biobank is not necessarily the same as performing licensed medical or pharmaceutical activities. Regulatory obligations depend on the actual services, procedures and products involved.
Russian judicial decisions concerning cryopreserved biological material demonstrate that human biological specimens cannot always be treated as ordinary inheritable property. Comparative decisions such as S. and Marper v. United Kingdom and Evans v. United Kingdom further illustrate the importance of privacy, consent and control over stored biological material.
Ultimately, Russia's commercial biobank sector would benefit from a dedicated legal framework establishing clear licensing standards, donor protections, commercial-use conditions and long-term storage responsibilities.
13. Important legal references for academic research
| Reference | Research relevance |
|---|---|
| Federal Law No. 323-FZ (2011) | Medical consent and confidentiality |
| Federal Law No. 152-FZ (2006) | Genetic and personal-data protection |
| Federal Law No. 99-FZ (2011) | Licensing framework |
| Federal Law No. 180-FZ (2016) | Biomedical cellular products |
| Government Resolution No. 852 (2021) | Medical licensing |
| Government Resolution No. 547 (2022) | Pharmaceutical licensing |
| S. and Marper v. UK (2008) | DNA retention and privacy |
| Evans v. UK (2007) | Reproductive consent |
| Third Cassation Court, 29 April 2026, No. 8G-4098/2026 | Cryopreserved biological material and inheritance |
Further academic reading:
Marina N. Maleina (2020), Legal Status of the Biobank (Bank of Biological Materials of Human Origin), Higher School of Economics Law Journal, 1, 98–117. Read academic research.
E. A. Ostanina (2023), Biobank as a Legal Category. Read academic research.
Research qualification: This explanation distinguishes actual Russian legislation and judicial decisions from comparative European jurisprudence and academic proposals. It should not be interpreted as confirmation that Russia currently operates a standalone universal commercial-biobank licensing system.

comments